Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
39.83
+2.14 (5.68%)
At close: May 7, 2026, 4:00 PM EDT
39.76
-0.07 (-0.18%)
After-hours: May 7, 2026, 7:09 PM EDT
Sutro Biopharma Revenue
In the year 2025, Sutro Biopharma had annual revenue of $102.48M with 65.18% growth. Sutro Biopharma had revenue of $11.65M in the quarter ending December 31, 2025, a decrease of -21.35%.
Revenue (ttm)
$102.48M
Revenue Growth
+65.18%
P/S Ratio
6.44
Revenue / Employee
$748,058
Employees
137
Market Cap
659.90M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 102.48M | 40.44M | 65.18% |
| Dec 31, 2024 | 62.04M | -91.69M | -59.64% |
| Dec 31, 2023 | 153.73M | 85.96M | 126.84% |
| Dec 31, 2022 | 67.77M | 5.89M | 9.52% |
| Dec 31, 2021 | 61.88M | 19.16M | 44.84% |
| Dec 31, 2020 | 42.72M | -14.00K | -0.03% |
| Dec 31, 2019 | 42.74M | 4.32M | 11.24% |
| Dec 31, 2018 | 38.42M | -13.32M | -25.75% |
| Dec 31, 2017 | 51.74M | -7.99M | -13.38% |
| Dec 31, 2016 | 59.73M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 311.71M |
| Arvinas | 262.60M |
| Crescent Biopharma | 11.88M |
| Prothena Corporation | 9.68M |
| Prime Medicine | 4.63M |
| ProKidney | 893.00K |
| Altimmune | 41.00K |
STRO News
- 7 days ago - Sutro Biopharma initiated with an Outperform at Mizuho - TheFly
- 14 days ago - Sutro Biopharma price target raised to $41 from $35 at Citizens - TheFly
- 18 days ago - Sutro Biopharma presents preclinical data across its pipeline of ADCs - TheFly
- 20 days ago - Sutro Biopharma price target raised to $35 from $23 at Citizens - TheFly
- 24 days ago - Sutro Biopharma management to meet with Citizens - TheFly
- 4 weeks ago - Sutro Biopharma initiated with an Outperform at Leerink - TheFly
- 6 weeks ago - Sutro Biopharma price target raised to $55 from $51 at Deutsche Bank - TheFly
- 6 weeks ago - Sutro Biopharma upgraded to Buy from Neutral at H.C. Wainwright - TheFly